Port Delivery System is noninferior to monthly ranibizumab injections

• Posted on: Dec 30 2021
• By: Saratoga Opthalmology
• Leave a response

Archway is phase 3 randomized, active-comparator, open-label, noninferiority study of the Port Delivery System (PDS) for neovascular age-related macular degeneration (nAMD).
Source: AAO

Posted in: Uncategorized